Literature DB >> 11923065

The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects.

Ann M Bode1, Zigang Dong.   

Abstract

Arsenic is a well-documented carcinogen that also appears to be a valuable therapeutic tool in cancer treatment. This creates a paradox for which no unified hypothesis has been reached regarding the molecular mechanisms that determine whether arsenic will act as a carcinogen or as an effectual chemotherapeutic agent. Much of our knowledge with respect to the actions of arsenic has been drawn from epidemiological or clinical studies. The actions of arsenic are likely to be related to cell type, arsenic species, and length and dose of exposure. Arsenic unquestionably induces apoptosis and may specifically target certain tumor cells. Research data strongly suggest that arsenic influences distinct signaling pathways involved in mediating proliferation or apoptosis, including mitogen-activated protein kinases, p53, activator protein-1 or nuclear factor kappa B. The primary purpose of this review is to examine recent findings, from this laboratory and others, that focus on the molecular mechanisms of arsenic's actions in cell transformation and as a therapeutic agent.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11923065     DOI: 10.1016/s1040-8428(01)00215-3

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  46 in total

1.  Arsenite causes down-regulation of Akt and c-Fos, cell cycle dysfunction and apoptosis in glutathione-deficient cells.

Authors:  Geetha M Habib
Journal:  J Cell Biochem       Date:  2010-05-15       Impact factor: 4.429

2.  Arsenic exposure and toxicology: a historical perspective.

Authors:  Michael F Hughes; Barbara D Beck; Yu Chen; Ari S Lewis; David J Thomas
Journal:  Toxicol Sci       Date:  2011-07-12       Impact factor: 4.849

Review 3.  Molecular and cellular targets.

Authors:  Ann M Bode; Zigang Dong
Journal:  Mol Carcinog       Date:  2006-06       Impact factor: 4.784

4.  Antioncogenic and Oncogenic Properties of Nrf2 in Arsenic-induced Carcinogenesis.

Authors:  Young-Ok Son; Poyil Pratheeshkumar; Ram Vinod Roy; John Andrew Hitron; Lei Wang; Sasidharan Padmaja Divya; Mei Xu; Jia Luo; Gang Chen; Zhuo Zhang; Xianglin Shi
Journal:  J Biol Chem       Date:  2015-09-18       Impact factor: 5.157

5.  Enhanced glutathione biosynthetic capacity promotes resistance to As3+-induced apoptosis.

Authors:  James A Thompson; Christopher C Franklin
Journal:  Toxicol Lett       Date:  2009-12-16       Impact factor: 4.372

6.  Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Exp Cell Res       Date:  2006-09-28       Impact factor: 3.905

7.  Carcinogenic metalloid arsenic induces expression of mdig oncogene through JNK and STAT3 activation.

Authors:  Jiaying Sun; Miaomiao Yu; Yongju Lu; Chitra Thakur; Bailing Chen; Ping Qiu; Hongwen Zhao; Fei Chen
Journal:  Cancer Lett       Date:  2014-01-14       Impact factor: 8.679

8.  Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide.

Authors:  Clement G Yedjou; Paul B Tchounwou
Journal:  Mol Cell Biochem       Date:  2009-05-15       Impact factor: 3.396

9.  The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel.

Authors:  Qian Liu; Hao Zhang; Lisa Smeester; Fei Zou; Matt Kesic; Ilona Jaspers; Jingbo Pi; Rebecca C Fry
Journal:  BMC Med Genomics       Date:  2010-08-13       Impact factor: 3.063

10.  Thermochemotherapy effect of nanosized As2O3/Fe3O4 complex on experimental mouse tumors and its influence on the expression of CD44v6, VEGF-C and MMP-9.

Authors:  Yiqun Du; Dongsheng Zhang; Hui Liu; Rensheng Lai
Journal:  BMC Biotechnol       Date:  2009-10-05       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.